
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **July 30, 2018**

SIGA TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or
organization)

0-23047
(Commission file number)

13-3864870
(I.R.S. employer identification no.)

27 East 62nd Street
New York, New York
(Address of principal executive offices)

10065
(Zip code)

Registrant's telephone number, including area code: (212) 672-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On July 30, 2018, SIGA Technologies, Inc., a Delaware corporation (the “Company”), entered into a modification (the “Modification”) of its 2011 procurement contract (contract #HHS0100201100001C) with the Biomedical Advanced Research and Development Authority (“BARDA”) of the United States Department of Health and Human Services.

The Modification provides for the exercise by BARDA of its option for a \$50 million payment to the Company relating to approval by the United States Food & Drug Administration of an extension to 84-month expiry for the Company’s orally-administered drug TPOXX® for the treatment of smallpox.

The foregoing description is qualified in its entirety by reference to the text of the Modification, which is attached hereto as Exhibit 10.1.

Item 9.01. Financial Statements and Exhibits

(d) The following exhibit is included in this report:

Exhibit No.	Description
10.1	Amendment of Solicitation/Modification of Contract 0015, dated July 30, 2018, to Agreement, dated May 13, 2011, between the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services and SIGA Technologies, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Daniel J. Luckshire
Name: Daniel J. Luckshire
Title: Chief Financial Officer

Date: August 1, 2018

Exhibit 10.1											
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT		1. CONTRACT ID CODE		PAGE OF PAGES							
				1	2						
2. AMENDMENT/MODIFICATION NO. 0015		3. EFFECTIVE DATE See Block 16C		4. REQUISITION/PURCHASE REQ. NO. OS221262							
5. PROJECT NO. (if applicable)											
6. ISSUED BY ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201		CODE ASPR-BARDA		7. ADMINISTERED BY (if other than Item 6) CODE ASPR-BARDA02							
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP code) SIGA TECHNOLOGIES, INC. 1385150 SIGA TECHNOLOGIES, INC. 35 E 6 35 E 62ND ST NEW YORK NY 100658014		(x)		9A. AMENDMENT OF SOLICITATION NO.							
CODE 1385150				9B. DATED (SEE ITEM 11)							
				10A. MODIFICATION OF CONTRACT/ORDER NO. HHSO10020110001C							
FACILITY CODE		X		10B. DATED (SEE ITEM 13)							
1385150				05/13/2011							
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS											
<input type="checkbox"/> The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers <input type="checkbox"/> is extended, <input type="checkbox"/> is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.											
12. ACCOUNTING AND APPROPRIATION DATA (if required) 2018.199TWN.26402		Net Increase:		\$50,000,000.00							
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.											
CHECK ONE	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.										
	B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)										
X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: 52.217-7 Option for Increased Quantity Separately Priced Line Item; FAR 1.605-1 – Mutual Agreement										
	D. OTHER (Specify type of modification and authority)										
E. IMPORTANT: Contractor <input type="checkbox"/> is not, <input checked="" type="checkbox"/> is required to sign this document and return <u>1</u> copies to the issuing office.											
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible)											
Tax ID Number: 13-3864870 DUNS Number: 932651516 PURPOSE: This modification is to exercise option CLIN 0011, B.5. Price schedule, Payment for FDA Approval for extension to 84-Month Expiry Product, as described in Section C.7.1 (NSP). <table style="width: 100%;"> <tr> <td>FUNDS ALLOTTED PRIOR TO MOD #15</td> <td style="text-align: right;">\$472,320,688.00</td> </tr> <tr> <td>FUNDS ALLOTTED WITH MOD #15</td> <td style="text-align: right;">\$50,000,000.00</td> </tr> <tr> <td>TOTAL FUNDS ALLOTTED TO DATE</td> <td style="text-align: right;">\$522,320,688.00 (Changed)</td> </tr> </table> EXPIRATION DATE: September 24, 2020 (Unchanged) Continued ... Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect						FUNDS ALLOTTED PRIOR TO MOD #15	\$472,320,688.00	FUNDS ALLOTTED WITH MOD #15	\$50,000,000.00	TOTAL FUNDS ALLOTTED TO DATE	\$522,320,688.00 (Changed)
FUNDS ALLOTTED PRIOR TO MOD #15	\$472,320,688.00										
FUNDS ALLOTTED WITH MOD #15	\$50,000,000.00										
TOTAL FUNDS ALLOTTED TO DATE	\$522,320,688.00 (Changed)										
15A. NAME AND TITLE OF SIGNER (Type or print) Dennis E. Hruby CSO			16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) ELIZABETH STEINER								
15B. CONTRACTOR/OFFEROR		15C. DATE SIGNED		16B. UNITED STATES OF AMERICA							
				16C. DATE SIGNED							

/s/ Dennis E. Hruby		/s/ Elizabeth Steiner	
(Signature of person authorized to sign)	30 Jul 2018	(Signature of Contracting Officer)	7/30/18
NSN 7540-01-152-8070		STANDARD FORM 30 (REV. 10-83)	
Previous edition unusable		Prescribed by GSA	
		FAR (48 CFR) 53.243	

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED

PAGE OF

HHSO100201100001C/0015

2

2

NAME OF OFFEROR OR CONTRACTOR

SIGA TECHNOLOGIES, INC. 1385150

ITEM NO. (A)	SUPPLIES/SERVICES (B)	QUANTITY (C)	UNIT (D)	UNIT PRICE (E)	AMOUNT (F)
	<p>CONTRACT FUNDED THROUGH September 24, 2020 (Unchanged)</p> <p>Total contract value is changed from Not To Exceed \$472,320,688.00 by \$50,000,000.00 to \$522,320,688.00.</p> <p>1) This option is being exercised in accordance with Statement of Objectives, Section C.7.1.1 and corresponding Section B.5. Price schedule, CLIN 0011, because SIGA completed the contract requirement for FDA Approval for extension to 84-Month Expiry Product on July 13, 2018 by receiving NDA approval from the FDA.</p> <p>2) By exercising the option for CLIN 0011 under the terms of this contract the total amount being obligated under this modification for this option FFP CLIN (0011) is \$50,000,000 (FFP).</p> <p>All other terms and conditions of contract HHSO1002011000010 remain unchanged.</p> <p>END OF MODIFICATION 0015 TO HHSO100201100001C Delivery: 06/07/2018 Delivery Location Code: HHS/OS/ASPR HHS/OS/ASPR 200 C St SW WASHINGTON DC 20201 US</p> <p>Appr. Yr.: 2018 CAN: 199TWNP Object Class: 26402 FOB: Destination Period of Performance: 06/28/2016 to 09/24/2020</p> <p>Add Item 7 as follows:</p> <p>ASPR-18-02825 -- Exercise Option CLIN 0011 under SIGA Technologies contract HHSO100201100001C Obligated Amount: \$50,000,000.00</p>				\$50,000,000.00

